OBJECTIVE To describe the epidemiology of nosocomial infections in children′s hospital.METHODS We performed a prospective and retrospective analysis to determine the prevalence of nosocomial infection.Data were collected from 2000 to 2007 in hospitalized cases.RESULTS The incidence of nosocomial infections was 3.43%,from then 40.27% were upper respiratory infections,28.94% of gastrointestinal infections,and 17.61%% bronchitis and pneumonia.The incidence had a tendency decreaseing P

OBJECTIVE To determine the extra-lengh of stay and the economic loss for nosocomial infections of group A rotavirus in children′s hospital. METHODS We performed a 1∶1 case-control study to determine the cost of nosocomial rotavirus infection. Data of hospitalized cases were collected from Jan 1 2007 to Dec 31 2007. RESULTS The average medical expenses in case and control group were 7589 yuan and 5319 yuan,the average increased cost per case was 2269 yuan,the expenses for medicine,treatment,laboratory test and bed accounted for 47.42%,19.96%,17.10% and 9.03%,respectively (P

As human microbiome research advances, a large body of evidence shows that microorganisms are closely related to human health. Probiotics were discovered and used as foods or dietary supplements with health benefits in the last century. Microorganisms have shown broader application prospects in human health since the turn of the century, owing to the rapid development of technologies such as microbiome analysis, DNA synthesis and sequencing, and gene editing. In recent years, the concept of "next-generation probiotics" has been proposed as new drugs, and microorganisms are considered as "live biotherapeutic products (LBP)". In a nutshell, LBP is a living bacterial drug that can be used to prevent or treat certain human diseases and indications. Because of its distinct advantages, LBP has risen to the forefront of drug development research and has very broad development prospects. This review introduces the varieties and research advances on LBP from a biotechnology standpoint, followed by summarizing the challenges and opportunities for LBP clinical implementations, with the aim to facilitate LBP development.
Humans ; Probiotics ; Dietary Supplements ; Bacteria ; Drug Development ; Biotechnology